Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung02)
Objective
1. To demonstrate the efficacy of rilvegostomig plus chemotherapy relative to pembrolizumab plus chemotherapy by assessment of OS 2. To demonstrate the efficacy of rilvegostomig plus chemotherapy relative to pembrolizumab plus chemotherapy by assessment of PFS 3.To characterize the efficacy of rilvegostomig plus chemotherapy relative to pembrolizumab plus chemotherapy by assessment of OS 4.To characterize the efficacy of rilvegostomig plus chemotherapy relative to pembrolizumab plus chemotherapy by assessment of PFS 5.To compare the efficacy of rilvegostomig plus chemotherapy relative to pembrolizumab plus chemotherapy by assessment of PFS2
